SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ray Rueb who wrote (20344)12/27/2004 10:25:28 AM
From: puborectalis  Read Replies (1) of 78595
 
DRUG STOCKS: "Novartis (NVS) has exhibited strong relative strength
in recent weeks, in spite of the pharma industry's woes. The stock is just under
its 52-week high of $50.47, something that can't be said for many other
large-cap drug stocks. Novartis has several promising drugs in various stages of
development including a potential blockbuster blood-pressure drug. Future growth
in this industry depends on development of new products, and NVS has a total of
79 drug projects in their pipeline, including 61 that are in Phases II, III or
FDA registration. We think these products will fuel NVS' future growth. Last
month I increased my 12- to 18-month target price to $69, as revenues and
earnings should continue to grow. As the cloud lifts from big pharma, we think
Novartis will benefit. NVS is a strong buy below $55."

--Eric Dany, The Stock Prospector
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News